fbpx
 

January 11, 2017

VetDC, Inc., a veterinary cancer therapeutics company, announced yesterday that the U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) has granted a conditional approval of Tanovea-CA1 (rabacfosadine for injection) for the treatment of lymphoma in dogs. Tanovea-CA1 is anticipated to be available to veterinarians in the spring of 2017.

“This is a significant milestone for VetDC, and we are excited to announce the first ever FDA-approved drug for canine lymphoma,” said Steven Roy, VetDC’s president and CEO. “We look forward to introducing Tanovea-CA1 to the veterinary cancer community in the months to come.”

“The conditional approval of Tanovea-CA1 represents a first on multiple levels for veterinary oncology, and we eagerly anticipate adding this very active and promising new drug to our lymphoma fighting arsenal,” noted Dr. Philip J. Bergman, a board-certified veterinary oncologist at VCA-Katonah Bedford Veterinary Center in Bedford Hills, New York.

Share This Story On:

Digital Guide

CBD Trends

This digital guide provides valuable information on the subject of CBD, including content on dosage and the importance of being fully transparent about the product’s origin

Dog & Cat Needs

With dogs and cats being members of the family, there's vital information to know in order to serve their pet parents.

Pet Nutrition

Discover how science, technology and pet owning lifestyles are changing the industry.

Enews Subscribe

34841
close
Subscribe To Pet Age
Sign up for the weekly e-newsletter, print magazine and more. Sign Up